Genentech halted a clinical study yesterday after ovarian cancer patients suffered serious side effects. After the announcement, Genentech's...
Genentech halted a clinical study yesterday after ovarian cancer patients suffered serious side effects.
After the announcement, Genentech’s shares fell. Avastin, approved for the treatment for colon cancer, was considered Genentech’s most promising drug.
Genentech said it stopped accepting participants in the ovarian cancer study after five of 44 patients suffered bowel tears.
The clinical trial was testing Avastin for ovarian cancer patients whose disease did not respond to chemotherapy drugs containing platinum.
Most Read Stories
- Woman, 71, lost in Olympics with dog, built shelter, ate ants
- 3 teens killed in Lynnwood crash from Mill Creek high school
- Foreign buyers drop off as Seattle housing market hits hottest tempo since 2006 bubble
- What drivers can and cannot do under Washington state's new distracted-driving law
- Are Seattle housing prices headed for a crash? | Jon Talton
Jim Reddich, an analyst with Friedman, Billings, Ramsey, said that Avastin might not reach its peak sales potential of $7 billion if doctors became worried about safety. The drug is expected to have sales of $1 billion this year.
Shares of Genentech fell $2.17 to $85.83.